Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts

被引:205
作者
Liao, RL
Jain, M
Teller, P
Connors, LH
Ngoy, S
Skinner, M
Falk, RH
Apstein, CS
机构
[1] Boston Univ, Sch Med, Cardiac Muscle Res Lab, Boston, MA 02118 USA
[2] Boston Univ, Sch Med, Amyloid Treatment & Res Program, Boston, MA 02118 USA
[3] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA
关键词
amyloidosis; physiology; nice; heart; diastole;
D O I
10.1161/circ.104.14.1594
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Primary (AL) amyloidosis is a plasma cell dyscrasia characterized by clonal production of immunoglobulin light chains (LC) resulting in the subsequent systemic deposition of extracellular amyloid fibrils. Cardiac involvement is marked by the hemodynamic pattern of impaired diastolic filling and restrictive cardiomyopathy. Although cardiac death in patients with AL amyloidosis is usually associated with extensive myocardial infiltration, the infiltration alone does not correlated with the degree of heart failure or survival. We hypothesized that circulating monoclonal LC may directly impair cardiac function, in addition to any mechanical effects of amyloid fibril deposition. Therefore, we examined the effects of amyloid LC proteins on diastolic and systolic cardiac function, as measured in an isolated mouse heart model. Methods and Results-LC were obtained from patients with nonamyloid disease or from those with noncardiac, mild cardiac. and severe cardiac involved AL amyloidosis. Saline or LC (100 mug/mL) was infused into a Langendorff-perfused, isovolumically contracting mouse heart. Saline and control, noncardiac, and mild-cardiac LC infusions did not alter ex vivo cardiac function. In contrast, infusion of sever cardiac LC resulted in marked impairment of ventricular relaxation with preservation of contractile function. Conclusion-These results demonstrate that infusion of LC from patients with AL amyloidosis result in diastolic dysfunction similar to that observed in patients with cardiac involved AL amyloidosis, and they suggest that amyloid LC proteins may contribute directly to the pathogenesis and the rapid progression of amyloid cardiomyopathy, independent of extracellular fibril deposition.
引用
收藏
页码:1594 / 1597
页数:4
相关论文
共 13 条
  • [1] [Anonymous], 1854, VIRCHOWS ARCH PATHOL, DOI DOI 10.1007/BF01930815
  • [2] FUNCTIONAL DEFECT IN AMYLOID HEART-DISEASE - STIFF-HEART SYNDROME[J]. CHEW, C;ZIADY, GM;RAPHAEL, MJ;OAKLEY, CM. AMERICAN JOURNAL OF CARDIOLOGY, 1975(04)
  • [3] Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: One-year follow-up in five patients[J]. Comenzo, RL;Vosburgh, E;Simms, RW;Bergethon, P;Sarnacki, D;Finn, K;Dubrey, S;Faller, DV;Wright, DG;Falk, RH;Skinner, M. BLOOD, 1996(07)
  • [4] ECHOCARDIOGRAPHIC FINDINGS IN SYSTEMIC AMYLOIDOSIS - SPECTRUM OF CARDIAC INVOLVEMENT AND RELATION TO SURVIVAL[J]. CUETOGARCIA, L;REEDER, GS;KYLE, RA;WOOD, DL;SEWARD, JB;NAESSENS, J;OFFORD, KP;GREIPP, PR;EDWARDS, WD;TAJIK, AJ. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1985(04)
  • [5] Familial and primary (AL) cardiac amyloidosis: Echocardiographically similar diseases with distinctly different clinical outcomes[J]. Dubrey, SW;Cha, K;Skinner, M;LaValley, M;Falk, RH. HEART, 1997(01)
  • [6] The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement[J]. Dubrey, SW;Cha, K;Anderson, J;Chamarthi, B;Reisinger, J;Skinner, M;Falk, RH. QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS, 1998(02)
  • [7] Falk R H, 2000, Adv Intern Med, V45, P107
  • [8] Medical progress - The systemic amyloidoses[J]. Falk, RH;Comenzo, RL;Skinner, M. NEW ENGLAND JOURNAL OF MEDICINE, 1997(13)
  • [9] FALK RH, 1999, AMYLOID AMYLOIDOSIS
  • [10] Targeted inactivation of Gαi does not alter cardiac function or β-adrenergic sensitivity[J]. Jain, M;Lim, CC;Nagata, K;Davis, VM;Milstone, DS;Liao, RL;Mortensen, RM. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2001(02)